These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 2395008)
1. Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study. Kellokumpu-Lehtinen P; Nordman E J Biol Response Mod; 1990 Aug; 9(4):439-44. PubMed ID: 2395008 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000. Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011 [TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744 [TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma. Trump DL; Ravdin PM; Borden EC; Magers CF; Whisnant JK J Biol Response Mod; 1990 Feb; 9(1):108-11. PubMed ID: 2319258 [TBL] [Abstract][Full Text] [Related]
5. Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma? Merimsky O; Shnider BI; Chaitchik S Mol Biother; 1991 Mar; 3(1):34-7. PubMed ID: 2069758 [TBL] [Abstract][Full Text] [Related]
6. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial. Figlin RA; deKernion JB; Maldazys J; Sarna G Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656 [TBL] [Abstract][Full Text] [Related]
7. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors. Canobbio L; Curotto A; Cannata D; Miglietta L; Lavarello A; Giglio C; Franchini R; Cussotto M; Boccardo F Anticancer Res; 1996; 16(1):541-4. PubMed ID: 8615668 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950 [TBL] [Abstract][Full Text] [Related]
10. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial]. Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838 [TBL] [Abstract][Full Text] [Related]
11. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064 [TBL] [Abstract][Full Text] [Related]
13. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Amato RJ; Morgan M; Rawat A Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152 [TBL] [Abstract][Full Text] [Related]
15. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547 [TBL] [Abstract][Full Text] [Related]
16. Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose. Hamada I; Kato M; Okada K Anticancer Res; 2002; 22(4):2429-36. PubMed ID: 12174939 [TBL] [Abstract][Full Text] [Related]
17. Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer. Kellokumpu-Lehtinen P; Nordman E Cancer Detect Prev; 1988; 12(1-6):523-9. PubMed ID: 3180144 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma. Bruntsch U; de Mulder PH; ten Bokkel Huinink WW; Clavel M; Drozd A; Kaye SB; Renard J; van Glabbeke M J Biol Response Mod; 1990 Jun; 9(3):335-8. PubMed ID: 2116500 [TBL] [Abstract][Full Text] [Related]
20. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Fosså SD; Martinelli G; Otto U; Schneider G; Wander H; Oberling F; Bauer HW; Achtnicht U; Holdener EE Ann Oncol; 1992 Apr; 3(4):301-5. PubMed ID: 1390305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]